This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ASCO '11: Exelixis Drug Shrinks Ovarian Cancer

CHICAGO ( TheStreet) -- Exelixis (EXEL) and investors have been focused on the development of cabozantinib in prostate cancer, but Saturday, research was presented showing the experimental drug's activity in ovarian cancer.

Treatment with cabozantinib led to objective response, or significant tumor shrinkage, in 24% of patients with metastatic ovarian cancer, according to results from a phase II study reported at the American Society of Clinical Oncology (ASCO) annual meeting.

Another 29% of cabozantinib-treated patients had tumors that stopped growing or had minimal shrinkage, leading to an overall disease control rate of 53%. The median duration of response in the study has not yet been reached.

Seventy ovarian cancer patients were enrolled in the phase II study of cabozantinib, which also included patients with other forms of cancer. About half of ovarian cancer patients were previously treated with platinum-based chemotherapy and included patients with advanced disease that was no longer responding to platinums.

Two of 11 patients, or 18%, of patients with platinum-refractory disease achieved a confirmed tumor response. Ten of 36 patients, or 28%, with platinum sensitive disease achieved a partial tumor response.

Two ovarian cancer patients died during the study for reasons that investigators deemed related to treatment with cabozantinib. Another 37% of patients had to have their doses of cabozantinib reduced because the drug was causing too many side effects, which included diarrhea and fatigue.

Exelixis plans further studies of cabozantinib in ovarian cancer but details have not yet been disclosed. The company is focusing most of its near-term efforts on developing the drug in prostate cancer.

Prostate cancer data from this same phase II study will be reported at the ASCO meeting on Monday afternoon.

Cabozantinib is garnering a lot of attention from Wall Street investors because of previously released data from this mid-stage study demonstrating the drug's ability to both shrink and stabilize tumors but also fully or partly eliminate cancer that had spread to bone in patients.

Cabozantinib is a targeted cancer drug that works by blocking two different molecular pathways that tumors use to grow.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ECYT $3.95 -2.90%
EXEL $4.56 0.44%
NKTR $15.54 -3.70%
AAPL $93.16 -1.80%
FB $116.43 -0.26%


Chart of I:DJI
DOW 17,685.20 -145.56 -0.82%
S&P 500 2,055.98 -19.83 -0.96%
NASDAQ 4,759.3580 -45.9330 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs